Topical formulations and uses thereof

Abstract

Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.

What is claimed is: 
     
         1 . An ophthalmic formulation, comprising an active agent, a polyoxyl lipid or fatty acid and a polyalkoxylated alcohol. 
     
     
         2 . An ophthalmic formulation, comprising an active agent, and an ≧40 polyoxyl lipid or fatty acid. 
     
     
         3 . An ophthalmic formulation, comprising an active ingredient and a polyoxyl lipid or fatty acid; wherein said polyoxyl lipid or fatty acid is present in an amount equal to greater than 1% of said formulation. 
     
     
         4 . An ophthalmic formulation, comprising an active agent and a polyoxyl lipid or fatty acid;
 wherein said formulation comprises nanomicelles.   
     
     
         5 . An ophthalmic formulation, comprising an active agent, 0.05-5% of one or more selected from the group consisting of HCO-40, HCO-60, HCO-80, HCO-100, polyoxyl 40 stearate and polyoxyl 35 castor oil; and about 0.01-0.1% octoxynol-40. 
     
     
         6 . The ophthalmic formulation of any of the preceding claims, wherein said active agent is one or more selected from the group consisting of calcineurin inhibitors, mTOR inhibitors, peptides, eicosanoids (e.g. prostacyclins and prostaglandins), anti-inflammatory drugs (such as NSAIDS), autonomic drugs (e.g. beta-blockers, alpha-blockers, beta-agonists, and alpha-agonists), biologics, gene therapy agents (e.g. viral vectors), anti-infectives (e.g. antifungals, antibiotics, and antivirals), retinoids, RNAi, photo sensitizers, steroids (e.g., estrogens and derivatives thereof, and corticosteroids), mixture drugs, immuno-modulators, chemotherapeutic agents, G-coupled protein receptor antagonists, receptor tyrosine kinase (RTK) inhibitors, growth hormone inhibitors, integrin inhibitors, Sdf1/CXCR4 pathway inhibitors, and nACh receptor antagonists, resolvins (or resolvin-like compounds), lipoxins, and oxylipins. 
     
     
         7 . The ophthalmic formulation of any of the preceding claims, wherein said active agent is a resolvin. 
     
     
         8 . The ophthalmic formulation of any of the preceding claims, wherein said active agent is compound 1001. 
     
     
         9 . The ophthalmic formulation of any of the preceding claims, wherein said active agent is one or more selected from the group consisting of cyclosporine A, voclosporin, ascomycin, tacrolimus, pimecrolimus, an analog thereof, or a pharmaceutically acceptable salt thereof. 
     
     
         10 . The ophthalmic formulation of any of the preceding claims, wherein said active agent is cyclosporine A 
     
     
         11 . A method of treating or preventing an ocular disease or condition, said method comprising topically administering a formulation of any of the preceding claims. 
     
     
         12 . A method of manufacturing an ophthalmic formulation comprising liquefying/melting and mixing (a) a polyoxyl lipid or fatty acid, (b) a polyalkoxylated alcohol and (c) an active agent and subsequently adding a buffer and a saline.